Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NCT00109603 ·Status: COMPLETED ·Phase: NA

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

NCT01709084 ·Status: COMPLETED ·Phase: PHASE3

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

NCT01906255 ·Status: COMPLETED

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

NCT00551655 ·Status: COMPLETED

PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5

NCT02149888 ·Status: COMPLETED ·Phase: PHASE4

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

The Women TDF-FTC Benchmark Study

NCT05057858 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Open Label Extension (OLE) of the TDF2 Study, Botswana

NCT04318210 ·Status: COMPLETED ·Phase: NA

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850 ·Status: COMPLETED ·Phase: PHASE2

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

NCT03227861 ·Status: COMPLETED ·Phase: PHASE3

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01533259 ·Status: COMPLETED ·Phase: PHASE3

Biomarkers for Event-driven PrEP Adherence

NCT04298697 ·Status: COMPLETED ·Phase: PHASE4

The Cellular Pharmacology of F-TAF in Dried Blood Spots

NCT02962739 ·Status: COMPLETED ·Phase: PHASE1

Emtricitabine/Tenofovir Alafenamide as Salvage ART

NCT02556333 ·Status: TERMINATED ·Phase: PHASE2

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940 ·Status: COMPLETED ·Phase: PHASE3

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

NCT00089492 ·Status: COMPLETED ·Phase: PHASE2

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

NCT01266902 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

NCT01040091 ·Status: COMPLETED ·Phase: PHASE1

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

NCT06513312 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551 ·Status: COMPLETED ·Phase: PHASE3

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

NCT04644029 ·Status: TERMINATED ·Phase: PHASE3

The Benefits of Immediate Treatment Initiation Without Immunovirological Data Compared to Conventional BIC / FTC / TAF Treatment in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection

NCT05606055 ·Status: COMPLETED ·Phase: PHASE4